Success Metrics

Clinical Success Rate
93.2%

Based on 55 completed trials

Completion Rate
93%(55/59)
Active Trials
75(44%)
Results Posted
33%(18 trials)
Terminated
4(2%)

Phase Distribution

Ph early_phase_1
13
8%
Ph not_applicable
8
5%
Ph phase_1
62
36%
Ph phase_2
80
47%
Ph phase_3
6
4%

Phase Distribution

75

Early Stage

80

Mid Stage

6

Late Stage

Phase Distribution169 total trials
Early Phase 1First-in-human
13(7.7%)
Phase 1Safety & dosage
62(36.7%)
Phase 2Efficacy & side effects
80(47.3%)
Phase 3Large-scale testing
6(3.6%)
N/ANon-phased studies
8(4.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

78.6%

55 of 70 finished

Non-Completion Rate

21.4%

15 ended early

Currently Active

75

trials recruiting

Total Trials

171

all time

Status Distribution
Active(93)
Completed(55)
Terminated(15)
Other(8)

Detailed Status

Completed55
Recruiting54
Active, not recruiting21
Not yet recruiting16
Withdrawn11
unknown8

Development Timeline

Analytics

Development Status

Total Trials
171
Active
75
Success Rate
93.2%
Most Advanced
Phase 3

Trials by Phase

Early Phase 113 (7.7%)
Phase 162 (36.7%)
Phase 280 (47.3%)
Phase 36 (3.6%)
N/A8 (4.7%)

Trials by Status

enrolling_by_invitation21%
not_yet_recruiting169%
recruiting5432%
withdrawn116%
active_not_recruiting2112%
terminated42%
unknown85%
completed5532%

Recent Activity

Clinical Trials (171)

Showing 20 of 171 trialsScroll for more
NCT07610135Phase 1

Psilocybin Efficacy With or Without Pimavanserin Pretreatment

Not Yet Recruiting
NCT05698511Phase 1

Neural and Physiological Correlates of Psychedelic Sub-states

Active Not Recruiting
NCT07226232Phase 3

Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression

Not Yet Recruiting
NCT05370911Phase 1

Effects of Repeated Psilocybin Dosing in OCD

Active Not Recruiting
NCT06626139Phase 2

Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers

Recruiting
NCT06455293Phase 2

Psilocybin Therapy for Depression in Parkinson's Disease

Recruiting
NCT07336238Phase 2

Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies

Recruiting
NCT07607938Phase 1

Psilocybin as a Novel Therapy for Residual Anhedonia

Not Yet Recruiting
NCT07332143Phase 2

Psilocybin-Assisted Therapy

Not Yet Recruiting
NCT07506395Phase 1

Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder

Recruiting
NCT05227612Phase 1

Psilocybin-assisted CBT for Depression

Completed
NCT06386003Phase 2

Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD

Not Yet Recruiting
NCT02037126Phase 2

Psilocybin-facilitated Treatment for Cocaine Use

Completed
NCT06299319Phase 1

Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD

Enrolling By Invitation
NCT06885996Phase 2

Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence

Not Yet Recruiting
NCT07216404Phase 2

Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer

Recruiting
NCT05322954Phase 1

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

Terminated
NCT05947383Phase 2

Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer

Active Not Recruiting
NCT05220046Phase 1

Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers

Active Not Recruiting
NCT06303739Phase 3

Psilocybin-Assisted Therapy in Treatment-Resistant Depression

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
171